Hepato-Pancreato-Biliary Surgery, Northeast Georgia Health System, Gainesville, GA
Gainesville, GA
Joined June 2009
- Tweets593
- Following325
- Followers352
- Likes1.6K
Nelson Royall, MD FACS retweeted
Adj HIPEC with Ox during 30 minutes did not improve the Recurrence Free Survival in COLOPEC trial, however adjuvant HIPEC with MMC improved the locoregional control rate at 3 y in HIPECT4 trial. jamanetwork.com/journals/jam…
Nelson Royall, MD FACS retweeted
Happy to share our work from @metrohealthCLE (FREE download from @SurgJournal until December 23!) on #MALS.
For MALS surgeons out there, are you routinely performing a ganglionectomy and lymphadenectomy?
@jamiepdecicco @fnuraja @MalsNational authors.elsevier.com/a/1i1K6…
38%Yes
62%No (MAL release only)
8 votes • Final results Nelson Royall, MD FACS retweeted
Today: #CAMINO trial #CRLM published in @TheLancetOncol; great team effort with @EAHPBA surgeons & radiologists from 14 centers 🇳🇱🇳🇴🇮🇹🇧🇪
✅#MRI changes clinical management in 32% of 298 patients scheduled for #surgery / #ablation of #colorectal #livermetastases based on CT only.
✅Results confirmed by “blinded” expert panel.
doi.org/10.1016/S1470-2045(2… – at Amsterdam, The Netherlands
Nelson Royall, MD FACS retweeted
🔥of the press: Molecular profiling in cholangiocarcinoma: a practical guide to next-generation sequencing
@OncologyAdvance
Cancer Treatment Reviews
doi.org/10.1016/j.ctrv.2023.…
👉GA are actionable in 30–50% of CCAs
👉we provide practical advice on NGS use & a detailed overview of frequently used NGS tests
@myESMO @EASLnews @ILCAnews @curecc #livertwitter
Nelson Royall, MD FACS retweeted
Effect of HIPEC on Cytoreductive Surgery in Gastric Cancer With Synchronous Peritoneal Metastases: GASTRIPEC-I Phase III
@JCO_ASCO
doi.org/10.1200/JCO.22.02867
❓to do or not to do
👉HIPEC improves PFS, but not OS
👉Subgroup may benefit more, PCI ≥7
🧐Debate continues..
@myESMO
Nelson Royall, MD FACS retweeted
#ESMO23
MATTERHORN study: Perioperative durvalumab+FLOT in gastric/GEJ cancer
Durvalumab vs Placebo
pCR➡️19.0% vs 7.0%✅
R0 resection➡️similar (86%)
Presented by. Dr. Salah-Eddin Al-Batran
@myESMO @oncodaily @VJOncology @Oncoinfo_it @OncoAlert
Nelson Royall, MD FACS retweeted
Should pts w/ #idiopathic #pancreatitis undergo EUS? How often #surgery 🔪 required?
#PICUS trial: 105 pts IAP, 24 centers 🇳🇱; EUS found a cause in 32%; biliary (24%) - #cholecystectomy, chronic pancreatitis (7%), and neoplasm (3%) - #pancreatoduodenectomy
IAP recurrence in 1-year:
17% with negative EUS ❌
6% with positive EUS ✅
➡️academic.oup.com/bjs/advance… – at Amsterdam, The Netherlands
Nelson Royall, MD FACS retweeted
The first ever Radiomics 👾 preoperative fistula risk score !!!
Development 🇳🇱 and external validation 🇮🇹
🐳 The radiomics-based preop FRS performed similarly to the existing scores ( ROC 0.8)
💪 Great added value considering only CT derived data!
academic.oup.com/bjsopen/art…
Nelson Royall, MD FACS retweeted
🔥off the press: Tislelizumab vs Sorafenib as 1st line Treatment for HCC
@JAMAOnc
doi.org/10.1001/jamaoncol.20…
👉ORR: 14.3% vs 5.4%
👉mOS: 15.9 vs 14.1mo
🧐non-inferiority, in line with Nivo & Durva, but we need a "niche" or a biomarker...
@myESMO @EASLedu @ILCAnews #livertwitter
Nelson Royall, MD FACS retweeted
We know that the risk of small intestinal NETs (siNETs) is increased among 1st degree relatives - I am following a few families. This GWAS study identified 4 novel risk loci for small intestinal NETs including a missense mutation in LGR5. Very interesting
sciencedirect.com/science/ar…
Nelson Royall, MD FACS retweeted
Outcomes of pancreatic cancer with liver oligometastasis - Takeda - 2023 - Journal of Hepato-Biliary-Pancreatic Sciences - Wiley Online Library onlinelibrary.wiley.com/doi/… – at Nicaragua
Nelson Royall, MD FACS retweeted
Phase I/IIa Trial of Yttrium-90 Radioembolization in
Combination with Durvalumab for HCC
@CCR_AACR
10.1158/1078-0432.CCR-23-0581
🔎🇰🇷, 24pts
👉mOS n.r.; mPFS 6.9 mo
👉CR: 29.2%, PR: 54.2%
👉clinically feasible & encouraging efficacy
@myESMO @EASLedu @ILCAnews #livertwitter
Nelson Royall, MD FACS retweeted
Important paper. Can ChatGTP give patients the wrong information. Study finds nearly a third of recs were not concordant with NCCN guidelines. Garbage in ➡️ garbage out. We saw this during Covid. @JAMAOnc @SWOG @DavendraSohal jamanetwork.com/journals/jam…
Nelson Royall, MD FACS retweeted
The role of adjuvant chemotherapy (AC) in patients with ampullary adenocarcinoma (AA) remains controversial. This study aimed to determine if AC improve the prognosis of patients with resected AA.
Read at: journals.lww.com/journalacs/…
Great overview of role of #surgery in #PancreasCancer with metastases. Limited data and need trials initiated to guide decisions @AHPBA @IHPBA sciencedirect.com/science/ar…
Nelson Royall, MD FACS retweeted
Nelson Royall, MD FACS retweeted
JUST OUT! Honored to serve as the senior author in @TheLancet re: Phase 3 FRESCO-2 #fruquintinib with improved OS and PFS. thelancet.com/journals/lance…
Just a joy to work with @adasarimd @MDAndersonNews @hutchmed @TakedaOncology. @VUMCDiscoveries @VUMC_Cancer #crcsm #CancerResearch
Nelson Royall, MD FACS retweeted
CA19-9 Response to First-Line #Neoadjuvant #FOLFIRINOX and Second-Line #Gemcitabine / #NabPaclitaxel for Patients with Operable #PancreaticCancer @SamThaljiMD @isteaus @MCWSurgery @MedicalCollege
rdcu.be/ddOte #VisualAbstract
Nelson Royall, MD FACS retweeted
Drainage of large walled off pancreatic necroses 🥎 a RCT from 🇩🇰
EUS guided Plastic 🤜🤛 LAMS
🟰 technical success (95 / 100%); adverse events and length of stay
🤔 for large WON are LAMS not superior?! Want to hear comments from my endo friends!
gut.bmj.com/content/72/6/116…
Nelson Royall, MD FACS retweeted
A twist in the management of small (1.1 to 2 cm) nonfunctional panc NETs or not...? This NCDB study suggested a survival benefit of resection after adjusting for various pre-op factors. I still support observation of NF pNETs ≤2 cm. What do others think?
jamanetwork.com/journals/jam…
